Bruce Ovbiagele1, Philip M Bath, Daniel Cotton, Nanshi Sha, Hans-Christoph Diener. 1. From the Department of Neurosciences, Medical University of South Carolina, Charleston, SC (B.O.); Stroke Trials Unit, University of Nottingham, United Kingdom (P.M.B.); Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT (D.C., N.S.); and Department of Neurology, University of Duisburg-Essen, Essen, Germany (H.-C.D.).
Abstract
BACKGROUND AND PURPOSE: To investigate the association of low estimated glomerular filtration rate (eGFR) <60 mL/min with recurrent stroke risk and to evaluate whether add-on renin-angiotensin system modulator therapy is associated with lower recurrent stroke risk in patients with low eGFR. METHODS: We analyzed the database of a multicenter trial involving 18,666 patients with recent ischemic stroke followed for 2.5 years. Primary outcome was time to first recurrent stroke. Independent associations of low eGFR with outcome in the entire cohort and add-on telmisartan treatment with outcome among those with low eGFR were evaluated. RESULTS:Low eGFR was observed in 3630 (20.1%) patients. Patients with low eGFR were older, more likely women, with a known history of hypertension. In unadjusted analyses, patients with low eGFR were more likely to experience a recurrent stroke (hazard ratio, 1.34; 95% confidence interval, 1.20-1.49). After adjusting for confounders, low eGFR was still associated with recurrent stroke but to a lesser extent (hazard ratio, 1.16; 95% confidence interval, 1.04-1.31). Telmisartan treatment among patients with low eGFR was not independently associated with recurrent stroke (hazard ratio, 1.08; 95% confidence interval, 0.89-1.31). CONCLUSIONS:Low eGFR is independently associated with a higher risk of recurrent stroke, but short-term add-on telmisartan therapy does not seem to mitigate this risk. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00153062.
RCT Entities:
BACKGROUND AND PURPOSE: To investigate the association of low estimated glomerular filtration rate (eGFR) <60 mL/min with recurrent stroke risk and to evaluate whether add-on renin-angiotensin system modulator therapy is associated with lower recurrent stroke risk in patients with low eGFR. METHODS: We analyzed the database of a multicenter trial involving 18,666 patients with recent ischemic stroke followed for 2.5 years. Primary outcome was time to first recurrent stroke. Independent associations of low eGFR with outcome in the entire cohort and add-on telmisartan treatment with outcome among those with low eGFR were evaluated. RESULTS: Low eGFR was observed in 3630 (20.1%) patients. Patients with low eGFR were older, more likely women, with a known history of hypertension. In unadjusted analyses, patients with low eGFR were more likely to experience a recurrent stroke (hazard ratio, 1.34; 95% confidence interval, 1.20-1.49). After adjusting for confounders, low eGFR was still associated with recurrent stroke but to a lesser extent (hazard ratio, 1.16; 95% confidence interval, 1.04-1.31). Telmisartan treatment among patients with low eGFR was not independently associated with recurrent stroke (hazard ratio, 1.08; 95% confidence interval, 0.89-1.31). CONCLUSIONS: Low eGFR is independently associated with a higher risk of recurrent stroke, but short-term add-on telmisartan therapy does not seem to mitigate this risk. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00153062.
Authors: Mariya P Tokmakova; Hicham Skali; Satish Kenchaiah; Eugene Braunwald; Jean L Rouleau; Milton Packer; Glenn M Chertow; Lemuel A Moyé; Marc A Pfeffer; Scott D Solomon Journal: Circulation Date: 2004-11-29 Impact factor: 29.690
Authors: Andrew S Levey; Josef Coresh; Ethan Balk; Annamaria T Kausz; Adeera Levin; Michael W Steffes; Ronald J Hogg; Ronald D Perrone; Joseph Lau; Garabed Eknoyan Journal: Ann Intern Med Date: 2003-07-15 Impact factor: 25.391
Authors: Vlado Perkovic; Toshiharu Ninomiya; Hisatomi Arima; Martin Gallagher; Meg Jardine; Alan Cass; Bruce Neal; Stephen Macmahon; John Chalmers Journal: J Am Soc Nephrol Date: 2007-09-05 Impact factor: 10.121
Authors: Salim Yusuf; Hans-Christoph Diener; Ralph L Sacco; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon Journal: N Engl J Med Date: 2008-08-27 Impact factor: 91.245
Authors: Elizabeth G Holliday; Matthew Traylor; Rainer Malik; Stephen Bevan; Jane Maguire; Simon A Koblar; Jonathan Sturm; Graeme J Hankey; Christopher Oldmeadow; Mark McEvoy; Cathie Sudlow; Peter M Rothwell; Josef Coresh; Pavel Hamet; Johanne Tremblay; Stephen T Turner; Mariza de Andrade; Madhumathi Rao; Reinhold Schmidt; Peter A Crick; Antonietta Robino; Carmen A Peralta; J Wouter Jukema; Paul Mitchell; Sylvia E Rosas; Jie Jin Wang; Rodney J Scott; Martin Dichgans; Braxton D Mitchell; W H Linda Kao; Caroline S Fox; Christopher Levi; John Attia; Hugh S Markus Journal: Stroke Date: 2014-10-28 Impact factor: 7.914
Authors: Zak Loring; Rebecca North; Anne S Hellkamp; Brett D Atwater; Camille G Frazier-Mills; Kevin P Jackson; Sean D Pokorney; Gervasio A Lamas; Jonathan P Piccini Journal: Pacing Clin Electrophysiol Date: 2020-11-05 Impact factor: 1.976
Authors: Bruce Ovbiagele; Lee H Schwamm; Eric E Smith; Maria V Grau-Sepulveda; Jeffrey L Saver; Deepak L Bhatt; Adrian F Hernandez; Eric D Peterson; Gregg C Fonarow Journal: J Am Heart Assoc Date: 2014-06-05 Impact factor: 5.501
Authors: Fred Stephen Sarfo; Linda Meta Mobula; Osei Sarfo-Kantanka; Sheila Adamu; Jacob Plange-Rhule; Daniel Ansong; Rexford Adu Gyamfi; James Duah; Bertha Abraham; David Ofori-Adjei Journal: J Neurol Sci Date: 2018-11-15 Impact factor: 3.181